glabridin has been researched along with Triple Negative Breast Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt, S; Chand, J; Dash, A; Dhiman, S; Goswami, A; Jamwal, A; Nandi, U; Singh, B; Wazir, P | 1 |
1 other study(ies) available for glabridin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Glabridin plays dual action to intensify anti-metastatic potential of paclitaxel via impeding CYP2C8 in liver and CYP2J2/EETs in tumor of an orthotopic mouse model of breast cancer.
Topics: Animals; Cell Line, Tumor; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2J2; Eicosanoids; Humans; Liver; Mice; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |